{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:06:09Z","timestamp":1783713969158,"version":"3.55.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:label\/>\n                  <jats:p>Patients with COVID-19-associated candidemia (CAC) in an intensive care unit (ICU) were matched 1:2 with those without candidemia, based on ICU admission date and length of stay in ICU being at least equal to that before candidemia in the corresponding case. The incidence rate of CAC was 2.34 per 1000 ICU days. Eighty cases could be matched to appropriate controls. In the multivariate conditional logistic regression analysis, age (P 0.001), and sequential organ failure assessment score (P 0.046) were the only risk factors independently associated with CAC. Tocilizumab and corticosteroids therapy were not independently associated with candidemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Lay summary<\/jats:title>\n                  <jats:p>In COVID-19 patients who need medical care in an intensive care unit, the risk of developing bloodstream Candida infection is higher in older patients and in those who have a more severe critical illness. Treatment with steroids or tocilizumab does not seem to affect the risk of candida bloodstream infection in these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mmy\/myab056","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T20:09:13Z","timestamp":1633032553000},"page":"1262-1266","source":"Crossref","is-referenced-by-count":33,"title":["Clinical characteristics and risk factors for COVID-19-associated Candidemia"],"prefix":"10.1093","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5309-6358","authenticated-orcid":false,"given":"Ali S","family":"Omrani","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar"},{"name":"Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junais","family":"Koleri","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar"},{"name":"Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Ben Abid","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar"},{"name":"Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Daghfel","sequence":"additional","affiliation":[{"name":"Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thasneem","family":"Odaippurath","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar"},{"name":"Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Zuhail","family":"Peediyakkal","sequence":"additional","affiliation":[{"name":"Critical Care Medicine, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Baiou","sequence":"additional","affiliation":[{"name":"Critical Care Medicine, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enas","family":"Sarsak","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar"},{"name":"Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elayana","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anvar","family":"Kaleeckal","sequence":"additional","affiliation":[{"name":"Business Intelligence Unit, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna A","family":"Almaslamani","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar"},{"name":"Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"2021120507330851000_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cmi.2020.04.023","article-title":"COVID-19 pandemic-a focused review for clinicians","volume":"26","author":"Cevik","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2021120507330851000_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID guideline for the diagnosis and management of candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2021120507330851000_bib3","article-title":"Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls","author":"Mastrangelo","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021120507330851000_bib4","article-title":"COVID-19-Associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions?","volume":"6","author":"Arastehfar","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2021120507330851000_bib5","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/myc.13258","article-title":"Epidemiology and mycology of candidaemia in non-oncological medical intensive care unit patients in a tertiary center in the united states: overall analysis and comparison between non-COVID-19 and COVID-19 cases","volume":"64","author":"Macauley","year":"2021","journal-title":"Mycoses"},{"key":"2021120507330851000_bib6","article-title":"Is the frequency of candidemia increasing in COVID-19 patients receiving corticosteroids?","volume":"6","author":"Riche","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2021120507330851000_bib7","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"The WHO rapid evidence appraisal for COVID-19 therapies working group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","year":"2020","journal-title":"JAMA"},{"key":"2021120507330851000_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2020.10.036","article-title":"Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis","volume":"27","author":"Tleyjeh","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2021120507330851000_bib9","first-page":"A2635","article-title":"Tocilizumab is associated with increased risk of fungal infections among critically ill patients with COVID-19","volume":"203","author":"Burger","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2021120507330851000_bib10","article-title":"The landscape of candidemia during the COVID-19 pandemic","author":"Seagle","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2021120507330851000_bib11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S2213-2600(20)30161-2","article-title":"Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations","volume":"8","author":"Phua","year":"2020","journal-title":"Lancet Resp Med"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myab056\/41113725\/myab056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/59\/12\/1262\/41282816\/myab056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/59\/12\/1262\/41282816\/myab056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T07:33:23Z","timestamp":1638689603000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/59\/12\/1262\/6384832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":11,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,10,8]]},"published-print":{"date-parts":[[2021,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myab056","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12]]},"published":{"date-parts":[[2021,10,8]]}}}